Alchemab Therapeutics raised an undisclosed amount in Series A extension financing, led by Ono Venture Investment along with existing investors. The funding will advance ATLX-2847 into clinical development.
Round Type
Series A
LondonBiotechnologyHealth CareTherapeuticsPharmaceuticalInvestors
Description
Alchemab Therapeutics, a London-based biopharmaceutical company, raised an undisclosed amount in Series A extension funding. The company intends to use the funds to advance ATLX-2847, a program for muscle atrophy, into clinical development. Backers included Ono Venture Investment and existing investors RA Capital, SV Health Investors, DCVC Bio, and Lightstone Ventures. The total amount raised to date is $114M.
Quick answer
Alchemab Therapeutics raised an undisclosed amount in a Series A round, dated September 9, 2025. Investors: Lilly, Ono Venture Investment, RA Capital, SV Health Investors, DCVC Bio and Lightstone Ventures. Alchemab Therapeutics is based in London, England, United Kingdom.
- How much did Alchemab Therapeutics raise?
- Alchemab Therapeutics raised an undisclosed amount in a Series A round on September 9, 2025.
- Who invested in Alchemab Therapeutics?
- Lilly, Ono Venture Investment, RA Capital, SV Health Investors, DCVC Bio and Lightstone Ventures are named as investors in this round.
- What does Alchemab Therapeutics do?
- Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development.
- Where is Alchemab Therapeutics based and how big is it?
- Alchemab Therapeutics is based in London, England, United Kingdom. Fundz records about 73 employees.
- Who are the decision-makers at Alchemab Therapeutics?
- Fundz holds 5 contacts at Alchemab Therapeutics, including the Director Antibody Discovery. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Pharmaceutical around the same time
Companies in the same sectors as Alchemab Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Acasti raised $4M (Funding Round) on October 23, 2025.
- ENA Respiratory raised $22M (Series B) on October 22, 2025.
- Minerva Neurosciences raised $200M (Funding Round) on October 21, 2025.
- ISOThrive raised $8.1M on October 10, 2025.
- TORL BioTherapeutics raised $96M (Series C) on October 7, 2025.
- Santhera Pharmaceuticals raised $21M (Funding Round) on September 23, 2025.
Who to call at Alchemab Therapeutics, and when
A new round usually means Alchemab Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Alchemab Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Alchemab Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Alchemab Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alchemab Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAlchemab Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.